Cynata Therapeutics has reached a pivotal moment in its clinical development journey, marking the completion of the 100-day primary evaluation period for all participants in its Phase 2 trial of CYP-001, a stem cell therapy targeting acute graft-versus-host disease. …
Cynata reaches crucial milestone as Phase 2 trial moves toward results
March 30, 2026 Australian Biotech
Latest Video
New Stories
-
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News -
Australia cannot deliver meaningful change until the levers of power are rebalanced
August 26, 2026 - - Latest News -
Insurers warn cut could hit Australians most likely to need cancer care
August 25, 2026 - - Latest News -
Australian study finds maternal RSV vaccination offers strong protection for infants
August 25, 2026 - - Latest News -
Acrux brings experienced clinical leader aboard to advance testosterone program
August 24, 2026 - - Australian Biotech -
Avecho moves to deepen global partnering push as CBD insomnia program advances
August 24, 2026 - - Australian Biotech -
July recommendations across oncology, rare disease and chronic care
August 24, 2026 - - Latest News